Back
Compare AU
Compare INCM vs. CNEW
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares S&P Global High Dividend Aristocrat ETF (INCM) and the VanEck China New Economy ETF (CNEW). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
INCM | CNEW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 111 | 66 |
Median incremental investment | $993.50 | $824.12 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,550.78 | $1,917.51 |
Average age group | > 35 | > 35 |
Key Summary
INCM | CNEW | |
|---|---|---|
Strategy | INCM.AX was created on 2018-10-18 by BetaShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. INCM.AX aims to track the performance of an index (before fees and expenses) that provides exposure to companies which have increased or maintained dividends every year for at least 10 consecutive years within developed markets outside of Australia. | CNEW.AX was created on 2018-11-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 104.46m in AUM and 122 holdings. CNEW.AX gives investors a portfolio of the most fundamentally sound companies in China having the best growth prospects in sectors making up the New Economy, namely technology, health care, consumer staples and consumer discretionary. CNEW.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index. |
Top 3 holdings | KRW - KOREAN WON (0 %) MSCI WORLD INDEX SEP26 (0 %) APPLE INC (6.10 %) | Suzhou Zelgen Biopharmaceuticals Co Ltd Class A (1.31 %) Shanghai Allist Pharmaceuticals Co Ltd Class A (1.19 %) Haisco Pharmaceutical Group Co Ltd Class A (1.19 %) |
Top 3 industries | Other (28.08 %) Information Technology (25.00 %) Health Care (8.90 %) | Information Technology (33.78 %) Health Care (27.01 %) Consumer Discretionary (20.43 %) |
Top 3 countries | United States (71.61 %) Switzerland (7.41 %) Japan (6.66 %) | China (100.00 %) |
Management fee | 0.45 % | 0.95 % |
Key Summary
INCM | CNEW | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | S&P World Ex-Australia High Yield Dividend Aristocrats Select Index - AUD - Benchmark TR Net | CSI MarketGrader China New Economy Index - CNY |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.95 % |
Price | $20.18 | $7.94 |
Size | $97.758 million | $100.985 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.51 % | 1.33 % |
Market | ASX | ASX |
First listed date | 22/10/2018 | 09/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
INCM | CNEW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 111 | 66 |
Median incremental investment | $993.50 | $824.12 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,550.78 | $1,917.51 |
Average age group | > 35 | > 35 |
Pros and Cons
INCM | CNEW | |
|---|---|---|
Pros |
| |
Cons |
|
INCM | CNEW |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |